| |
Monogram NS5A Resistance Test
|
| |
| |
Download the PDF here
Download the PDF here
HCV NS5A is commercially available and can be ordered direct from Monogram or through LabCorp. I have attached the HCV NS5A FAQ reference which includes test codes, CPT codes and other answers to questions about ordering the assay.
Coverage of Monogram assays varies by insurance carrier. Monogram offers the Gateway program which can perform a benefits investigation for patients to determine if testing will be paid for by their insurance. The Gateway number is 1-877-436-6243. The Gateway program also offers access to a patient assistance program for qualifying individuals with low income and no insurance.
see the attached FAQs for HCV NS5A & NS5B assay which is also available for patient testing.
HCV NS5A Resistance Testing
is available direct from Monogram or through LabCorp
· Clinicians should use their judgment to determine the clinical applicability of this assay. At this time, baseline resistance testing for NS5A inhibitors has not been formally recommended as the body of evidence continues to evolve
· turnaround time is approximately 7-10 days from sample receipt at Monogram Biosciences
· Monogram's Client Services group is available to answer questions. Call 1-800-777-0177 or visit the Monogram website at www.monogrambio.com
· The HCV NS5A assay was validated for use in August 2012
· commercially available in March of 2015
· The HCV NS5A assay is only indicated for HCV genotypes 1a and 1b
· The CPT codes for the HCV NS5A Drug Resistance Assay are 87902 and 87900. CPT coding may vary based on individual patient insurance plans. Please contact the specific insurance carrier for their requirements
· Coverage of Monogram assays varies by insurance carrier. Monogram offers the Gateway program which can perform a benefits investigation for patients to determine if testing will be paid for by their insurance. The Gateway number is 1-877-436-6243. The Gateway program also offers access to a patient assistance program for qualifying individuals with low income and no insurance
|
|
| |
| |
|
|
|
